Results 141 to 150 of about 14,917 (240)

Hypomethylating agents alone or in combination with venetoclax in very elderly acute myeloid leukemia patients: less treatment, better care? [PDF]

Ann Hematol
Tarantini F, Contento C, Vigna E, Carluccio V, Greco G, Pasciolla C, Ciuffreda L, Rossi G, Urbano MA, D'Ambrosio A, Aprile L, Gagliardi VP, Delia M, Attolico I, Carluccio P, Federico V, Bruzzese A, Di Renzo N, Gentile M, Tarantini G, Mele A, Guarini A, Melillo LMA, Carella AM, Pastore D, Frigeri F, Maggi A, Cumbo C, Specchia G, Musto P, Albano F.   +30 more
europepmc   +1 more source

Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy. [PDF]

Hemasphere
Vänttinen I, Saad J, Ruokoranta T, Kytölä S, Qin G, Tercan B, Ettala P, Partanen A, Pyörälä M, Rimpiläinen J, Siitonen T, Manninen M, Valk PJM, Huls G, Thorsson V, Heckman CA, Kontro M, Kuusanmäki H.   +17 more
europepmc   +1 more source

Case Report: Venetoclax combined with hypomethylating agents for the treatment of newly diagnosed with mixed-phenotype acute leukemia and a literature review. [PDF]

Front Oncol
Mi R, Guo S, Yang W, Wang L, Ma Y, Chen L, Li D, Wei X.   +7 more
europepmc   +1 more source

Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification. [PDF]

Leuk Res Rep
Sun J, Guo Z.
europepmc   +1 more source

Exposure-response analyses of venetoclax combined with hypomethylating agents in myelodysplastic syndromes: a retrospective study. [PDF]

Front Pharmacol
Tian JX, Zhang P, Wang XX, Li JW, Liu DX, Liu YY, Xiao ZJ, Miao WJ.   +7 more
europepmc   +1 more source

BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer [PDF]

, 2016
Gomes, AR, Gong, C, Lam, EW, Yao, S
core   +1 more source

Corrigendum to "Unveiling prognosis in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax through novel risk stratification" [Leukemia Research Reports 24 (2025) 100550]. [PDF]

Leuk Res Rep
Sun J, Guo Z.
europepmc   +1 more source

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN. [PDF]

Blood Neoplasia
Pemmaraju N, Phan LH, Fell G, Luskin MR, Swaminathan M, Pierce S, DiNardo C, Maiti A, Konopleva M, Lane AA.   +9 more
europepmc   +1 more source

Disparities in real-world treatment patterns of hypomethylating agents among patients with MDS in the United States. [PDF]

Blood Neoplasia
Mukherjee S, Dong W, Gerds AT, Carraway HE, Singh A, Advani AS, Mustafa Ali MK, Molina JC, Balderman S, Jain A, Caimi P, Anwer F, Sekeres MA, Koroukian SM.   +13 more
europepmc   +1 more source

Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia. [PDF]

Eur J Med Res
Shu W, Yang Q, He D, Li Y, Le J, Cai Q, Dai H, Luo L, Chen B, Gong Y, Jin D.   +10 more
europepmc   +1 more source